Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7858764 | 0.98 | MAPT (0.49) | MAPTGAACYP2C19CYP2C9NPSR1 | |
| SCHEMBL12495214 | 0.98 | LMNA (0.52) | MAPTGAACYP2C19CYP2C9NPSR1 | |
| SCHEMBL4055295 | 0.84 | ALDH1A1 (0.43) | MAPTGAACYP2C19CYP2C9NPSR1 | |
| SCHEMBL30839226 | 0.82 | KDM1A (0.48) | MAPTGAACYP2C19CYP2C9NPSR1 | |
| SCHEMBL1752645 | 0.79 | KDM1A (0.50) | GAACYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL1829575 | 0.79 | KDM1A (0.46) | GAACYP2C19CYP2C9NPSR1LMNA | |
| SCHEMBL11340048 | 0.79 | GAA (0.54) | MAPTGAANPSR1LMNASMN1; SMN2 | |
| SCHEMBL13802752 | 0.79 | CYP2D6 (0.53) | MAPTGAACYP2C19CYP2C9NPSR1 | |
| SCHEMBL27261568 | 0.79 | HTT (0.58) | MAPTGAALMNASMN1; SMN2HTT | |
| SCHEMBL29931822 | 0.79 | MEN1 (0.46) | CYP2C19LMNASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591550-A | Preparation method of molatinib and key intermediate | 沈阳药科大学 | 2025-03-11 | — | — | CN | claimed |
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | claimed |
| CN-117186472-A | High-temperature-resistant stretch-resistant colorful film and preparation method thereof | 新航涂布科技(苏州)有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-113912566-B | 1-pyrene formaldehyde morpholinyl aniline Schiff base compound and preparation method and application thereof | 淮阴师范学院 | 2023-09-19 | — | — | CN | claimed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | claimed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2021110614-A1 | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | claimed |
| CN-110357901-B | Aromatic ring vinyl thieno pyrimidine compound, preparation method and application of compound | 安徽医科大学 | 2020-06-23 | — | — | CN | claimed |
| CN-110357901-A | The preparation method and application of aromatic rings vinyl thiophene miazines compound and preparation, the compound | 安徽医科大学 | 2019-10-22 | — | — | CN | claimed |
| CN-109206427-A | Aromatic heterocycle vinyl Pyrazolopyrimidines, pharmaceutical preparation and preparation method and application | 安徽医科大学 | 2019-01-15 | — | — | CN | claimed |
| CN-108997247-A | A kind of preparation method of Rivaroxaban intermediate | 泰州申合泰尔生物医药有限公司 | 2018-12-14 | — | — | CN | claimed |
| CN-108707119-A | A kind of preparation method of Momelotinib | 抚顺大恒化工有限公司 | 2018-10-26 | — | — | CN | claimed |
| CN-105837515-B | A kind of preparation method of JAK inhibitor Momelotinib | 中国药科大学 | 2018-08-03 | — | — | CN | claimed |
| CN-106967074-A | CDK inhibitor | G1治疗公司 | 2017-07-21 | — | — | CN | claimed |
| CN-106008533-A | Cdk inhibitors | G1治疗公司 | 2016-10-12 | — | — | CN | claimed |
| CN-105837515-A | A preparing method of a JAK inhibitor Momelotinib | 中国药科大学 | 2016-08-10 | — | — | CN | claimed |
| CN-102648217-B | Low molecular weight polymers of multifunctional multiple graft monomers | CASTROL LTD. (GB) | 2015-11-25 | — | — | CN | claimed |
| CN-104672217-A | New linezolid intermediate, preparation method thereof, and linezolid synthesis method | BEIJING ZHONGHE MINJIAN PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-06-03 | — | — | CN | claimed |
| WO-2002028829-A2 | PEPTIDE DEFORMYLASE INHIBITORS | QUESTCOR PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR9, TLR5 | MAPT 4690/4885GAA 2868/4885CYP2C19 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.